Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TiTan: teclistamab + talquetamab versus daratumumab + lenalidomide after ASCT in MRD-positive newly diagnosed multiple myeloma
2025-525097-11-00Phase 3Authorised
- Sponsor
- Polish Myeloma Consortium
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of talquetamab, teclistamab, daratumumab and lenalidomide in multiple myeloma (MM) (2 arms), sponsored by Polish Myeloma Consortium. Primary endpoint: MRD-CR negativity with complete response at Month 12. Planned start Jul 2026; status: authorised.
02
Drugs
talquetamabteclistamabdaratumumablenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2025-525097-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525097-11-00.